Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | BCR | P11274 | 2/20 | 0.44 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19898031 | 0.85 | PDE2A (0.46) | PDE2AABL1BCRPTGESCHRM5 | |
| SCHEMBL19897978 | 0.79 | PDE2A (0.56) | PDE2ACREBBP | |
| SCHEMBL18103284 | 0.79 | PDE2A (0.56) | PDE2ACREBBP | |
| SCHEMBL19898059 | 0.79 | PDE2A (0.56) | PDE2ACREBBP | |
| SCHEMBL8513871 | 0.74 | MAT2A (0.46) | KLKB1ABL1BCRTYMSKCNH2 | |
| SCHEMBL19897991 | 0.74 | PDE2A (0.53) | PDE2A | |
| SCHEMBL19898047 | 0.74 | PDE2A (0.53) | PDE2A | |
| SCHEMBL18103206 | 0.74 | PDE2A (0.53) | PDE2A | |
| SCHEMBL19002057 | 0.73 | KLKB1 (0.48) | PDE2AKLKB1KCNH2 | |
| SCHEMBL8536085 | 0.73 | ACP1 (0.47) | KLKB1ABL1BCRKCNH2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3285581-B1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-11 | — | — | EP | claimed |
| US-10287269-B2 | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | claimed |
| US-20180057480-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-01 | — | — | US | claimed |
| EP-3285581-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-28 | — | — | EP | claimed |
| WO-2016154081-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | claimed |
| EP-3285581-B1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10287269-B2 | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287269-B2 | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180057480-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180057480-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180057480-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-01 | — | — | US | disclosed |
| EP-3285581-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016154081-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016154081-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057480-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE5A | PDE2A 1/4885KLKB1 3511/4885ABL1 2443/4885 |
| US-10287269-B2 | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | PDE2A 1/4885KLKB1 3511/4885ABL1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.